Clinical Scorecard: Single-nucleus RNA sequencing uncovers distinct molecular signatures associated with α-synucleinopathies and their related pathologies
At a Glance
Category
Detail
Condition
α-Synucleinopathies including Parkinson’s disease (idiopathic and LRRK2 mutation-associated) and multiple system atrophy
Key Mechanisms
Intracellular aggregation of α-synuclein forming Lewy pathology in neurons or oligodendroglial cytoplasmic inclusions; cell type-specific transcriptional changes revealed by single-nucleus RNA sequencing
Target Population
Individuals with idiopathic Parkinson’s disease, LRRK2 mutation-associated Parkinson’s disease, multiple system atrophy, and healthy controls
Care Setting
Neurological and neurodegenerative disease research and clinical neuropathology
Key Highlights
Idiopathic PD and LRRK2-PD share largely overlapping cell type-specific transcriptional signatures distinct from multiple system atrophy.
A specific deep cortical neuronal subtype expressing adrenoceptor alpha 2A shows concentrated differential gene expression in PD.
PDE10A is consistently downregulated across most cortical neurons in all three α-synucleinopathies studied.
Guideline-Based Recommendations
Diagnosis
Diagnosis of PD should follow National Institute of Neurological Disorders and Stroke and UK Parkinson’s Disease Society Brain Bank criteria.
Molecular diagnosis can consider LRRK2 mutation status in monogenic PD cases.
Management
Currently, no disease-modifying therapies exist for α-synucleinopathies; management remains symptomatic.
Understanding cell type-specific molecular signatures may guide future therapeutic development.
Monitoring & Follow-up
Monitoring of α-synuclein pathology presence and severity may inform disease progression, especially in LRRK2-PD.
Neuropathological assessment remains important for confirming α-synuclein inclusions.
Risks
Survival bias in dopaminergic neuron studies due to severe degeneration in substantia nigra pars compacta at terminal stages.
Limitations in detecting GBA mutations due to pseudogene homology in RNA sequencing.
Patient & Prescribing Data
Individuals with idiopathic PD, LRRK2 mutation-associated PD, and multiple system atrophy
No current disease-modifying treatments; molecular insights from transcriptional profiling may inform future targeted therapies.
Clinical Best Practices
Utilize single-nucleus RNA sequencing to identify cell type-specific gene expression changes in neurodegenerative disorders.
Consider brain regions with milder involvement, such as the neocortex, to avoid survival bias in neuronal studies.
Confirm genetic mutation status (e.g., LRRK2) to differentiate monogenic PD from idiopathic forms.
Integrate neuropathological evaluation of α-synuclein inclusions for accurate disease characterization.
by Gonzalo S Nido, Martina Castelli, Sepideh Mostafavi, Anna Rubiolo, Omnia Shadad, Guido Alves, Ole-Bjørn Tysnes, Irene H Flønes, Christian Dölle, Charalampos Tzoulis
